Pulmonary Tuberculosis
95
11
15
57
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
17 trials with published results (18%)
Research Maturity
57 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.1%
2 terminated out of 95 trials
96.6%
+10.1% vs benchmark
23%
22 trials in Phase 3/4
30%
17 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (95)
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BLMZ Chinese Cohort
A PAN-USR TB Multi-Center Trial
PanACEA - STEP2C -01
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
ATORvastatin in Pulmonary TUBerculosis
Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis
I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort
Ultra-Short Regimen for Elderly DS-TB
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
Novel Triple-dose Tuberculosis Retreatment Regimen
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial